Number 836 • January 2020

# Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Diclo 50 mg Enteric-Coated Tablet (DIN 00839183) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 17, 2020.** 

### **DICLOFENAC SODIUM**

#### **50 MG ENTERIC-COATED TABLET**

00000839183	APO-DICLO	APX	\$ 0.2024
00002352397	DICLOFENAC SODIUM	SNS	\$ 0.2024
00002302624	PMS-DICLOFENAC	PMS	\$ 0.2024
00002261960	SANDOZ DICLOFENAC	SDZ	\$ 0.2024
00000808547	TEVA-DICLOFENAC EC	TEV	\$ 0.2024
00000514012	VOLTAREN	NOV	\$ 0.9554

Alberta Blue Cross has been advised by Pharmascience Inc. and Teva Canada Ltd. that the shortages for pms-Nabilone 1 mg Capsule (DIN 02380919) and Teva-Nabilone 1 mg Capsule (DIN 02384892) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 17, 2020.** 

#### **NABILONE**

#### **1 MG ORAL TABLET**

00002380919	PMS-NABILONE	PMS	\$ 1.5513
00002384892	TEVA-NABILONE	TEV	\$ 1.5513
00000548375	CESAMET	VCL	\$ 6.9208

Alberta Blue Cross has been advised by Teva Canada Ltd. that the shortage for Teva-Carbamaz 200 mg Tablet (DIN 00782718) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 17, 2020.** 

## **CARBAMAZEPINE**

## **200 MG TABLET**

00002407515	TARO-CARBAMAZEPINE	TAR	\$ 0.2432
00000782718	TEVA-CARBAMAZ	TEV	\$ 0.2432
0000010405	TEGRETOL	NOV	\$ 0.4267

# Removal of temporary benefits from the ADBL

Due to the shortage of the following products, Teva-Nabilone 0.25 mg Capsule (DIN 02392925) manufactured by Teva Canada Ltd. and Cesamet 0.25 mg Capsule (DIN 02312263) manufactured by Bausch Health were added as temporary benefits for the Alberta Drug Benefit List (*ADBL*).

DIN	Product Description	Manufacturer
02393581	Act Nabilone 0.5 mg Oral Capsule	Actavis Pharma Company
02380900	pms-Nabilone 0.5 mg Oral Capsule	Pharmascience Inc.
02384884	Teva-Nabilone 0.5 mg Oral Capsule	Teva Canada Ltd.
02256193	Cesamet 0.5 mg Oral Capsule	Bausch Health

Actavis Pharma Company, Teva Canada Ltd. and Bausch Health have advised Alberta Blue Cross that the shortages of Act Nabilone 0.5 mg Oral Capsule (DIN 02393581), Teva-Nabilone 0.5 mg Oral Capsule (DIN 02384884) and Cesamet 0.5 mg Oral Capsule (DIN 02256193) have been resolved, respectively.

As a result, Teva-Nabilone 0.25 mg Capsule (DIN 02392925) and Cesamet 0.25 mg Capsule (DIN 02312263) will no longer be considered temporary benefits for the *ADBL* **after February 18, 2020**.

# When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit** ab.bluecross.ca/providers/pharmacy-home.php



